PharmAust Limited
The principal activities of the company are to develop its own drug discovery intellectual property, namely three platforms for the treatment of different types of cancers in humans and animals, as well as providing highly specialised medicinal and synthetic chemistry services on a contract basis to clients.
Market Cap approx. $15m at 0.8cents
Positive early trial stage results for its candidate cancer drug PAA-1. Trials involving both human and canine subjects. The drug is actually an already existing veterinary medicine being utilised for an alternative purpose. Agreements with others to further develop analogues of the drug.
The other part of the business, Epichem, appears to be performing well and is looking to expand in the next few years based on recent quarterly.
